Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Pharma-Cosmetic Union Officially Joins Rengo as Associate Organization
Japan’s largest labor confederation, Rengo, has approved the entry of the Japanese Federation of Pharmaceutical and Cosmetic Industry Workers’ Unions (Yakusho Rengo) as an associate organization without voting rights. The decision was made at Rengo’s regular convention on October 7.…
To read the full story
Related Article
- Pharma Labor Group Logs Wage Hikes of around 4% at July-End
August 24, 2026
- Pharma Labor Group Sees Wage Hikes in Low 4% Range as Talks Continue
April 7, 2026
- Japanese Pharma-Cosmetic Union Breaks from UA Zensen, Set to Join Rengo
September 25, 2025
ORGANIZATION
- Ex-JMA Vice President Takashi Hanyuda Dies at 78
August 27, 2026
- Pharma Labor Group Logs Wage Hikes of around 4% at July-End
August 24, 2026
- Biotech Group Calls for Post-IPO Startups to Get AMED Support
August 19, 2026
- EFPIA Executive Hails Japan’s Honebuto as “Blueprint” for Europe
August 17, 2026
- New Chuikyo Pharmacist Rep Urges 2027 Revision to Stay within 4-Minister Deal
August 3, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…